Marzena Welnicka-Jaskiewicz
Overview
Explore the profile of Marzena Welnicka-Jaskiewicz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
365
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Markiewicz A, Topa J, Popeda M, Szade J, Skokowski J, Welnicka-Jaskiewicz M, et al.
Acta Biochim Pol
. 2021 Aug;
68(3):385-392.
PMID: 34432400
Breast cancer (BC) is a heterogeneous disease with different molecular subtypes, which can be defined by oestrogen (ER), progesterone (PR) and human epidermal growth factor (HER2) receptors' status as luminal,...
2.
Nagel A, Szade J, Iliszko M, Elzanowska J, Welnicka-Jaskiewicz M, Skokowski J, et al.
Int J Mol Sci
. 2019 Apr;
20(8).
PMID: 30995757
The amplification of estrogen receptor alpha (ERα) encoded by the gene has been described as having a prognostic role in breast cancer patients. However, increased dosage of the gene (tested...
3.
Markiewicz A, Topa J, Nagel A, Skokowski J, Seroczynska B, Stokowy T, et al.
Cancers (Basel)
. 2019 Jan;
11(1).
PMID: 30634453
Circulating tumour cells (CTCs) can provide valuable prognostic information in a number of epithelial cancers. However, their detection is hampered due to their molecular heterogeneity, which can be induced by...
4.
Markiewicz A, Nagel A, Szade J, Majewska H, Skokowski J, Seroczynska B, et al.
Transl Oncol
. 2018 Apr;
11(3):722-731.
PMID: 29660692
Intratumoral heterogeneity of breast cancer remains a major challenge in successful treatment. Failure of cancer therapies can also be accredited to inability to systemically eradicate cancer stem cells (CSCs). Recent...
5.
Czapiewski P, Welnicka-Jaskiewicz M, Seroczynska B, Skokowski J, Sejda A, Szade J, et al.
Pol J Pathol
. 2015 Dec;
66(3):269-75.
PMID: 26619106
CD99 is a protein initially described in the Ewing sarcoma family of tumors, but growing evidence has shown its expression in other tumors of mesenchymal, hematopoietic and even epithelial origin....
6.
Bednarz-Knoll N, Nastaly P, Zaczek A, Stoupiec M, Riethdorf S, Wikman H, et al.
Oncotarget
. 2015 Aug;
6(29):26789-803.
PMID: 26305673
Interactions between cancer cells and microenvironment are emerging issue in tumor progression. Aldehyde dehydrogenase 1 (ALDH1) is a recognized cancer stem cell marker but little is known about its role...
7.
Markiewicz A, Welnicka-Jaskiewicz M, Seroczynska B, Skokowski J, Majewska H, Szade J, et al.
Am J Transl Res
. 2015 Jan;
6(6):793-808.
PMID: 25628790
Epithelial-mesenchymal transition (EMT) was shown to enhance metastatic abilities of cancer cells, but it remains elusive in clinical samples. Moreover, EMT is rarely studied in lymph node metastases (LNM), thus...
8.
Markiewicz A, Ksiazkiewicz M, Welnicka-Jaskiewicz M, Seroczynska B, Skokowski J, Szade J, et al.
PLoS One
. 2014 Apr;
9(4):e93901.
PMID: 24709997
Introduction: Circulating tumor cells (CTCs) that present mesenchymal phenotypes can escape standard methods of isolation, thus limiting possibilities for their characterization. Whereas mesenchymal CTCs are considered to be more malignant...
9.
Markiewicz A, Ksiazkiewicz M, Seroczynska B, Skokowski J, Szade J, Welnicka-Jaskiewicz M, et al.
Cancers (Basel)
. 2013 Nov;
5(4):1485-503.
PMID: 24217115
Breast cancers can metastasize via hematogenous and lymphatic routes, however in some patients only one type of metastases are detected, suggesting a certain proclivity in metastatic patterns. Since epithelial-mesenchymal transition...
10.
Markiewicz A, Welnicka-Jaskiewicz M, Skokowski J, Jaskiewicz J, Szade J, Jassem J, et al.
PLoS One
. 2013 Aug;
8(8):e72219.
PMID: 23951298
Introduction: Amplification of the ESR1 gene, coding for estrogen receptor alpha, was shown to predict responsiveness to tamoxifen, however its prognostic impact in breast cancer patients has not been thoroughly...